


KNOW About the Impact of Invasive Candidiasis (IC)

IC includes¹



Candidemia
(bloodstream infections)



Deep-seated candidiasis
(affecting eyes, heart, brain, GI, etc.)

Epidemiology



1 —
2 —
3 —

2nd

most common
bloodstream infection²




15%-40%

mortality rate¹



\$40,000

average cost per
episode¹



Non-*albicans* species on the rise (more resistant)^{3*}

Resistance is a serious threat!⁴



7%
of IC isolates are
resistant to an
antifungal⁴



*Species distribution varies by geographic region and patient population.

1. Gonazal-Lara MF, Ostrosky-Zeichner L. *Semin Respir Crit Care Med.* 2020;41:3-12. 2. Magill SS, et al. *Engl J Med.* 2018;379:1732-1744. 3. Pfaller MA, et al. *Open Forum Infect Dis.* 2019;6:S79-S94. 4. CDC. Antibiotic resistance threats in the United States, 2019. 5. Alexander BA, et al. *Clin Infect Dis.* 2013;56:1724-1732. 6. Pinhati HMS, et al. *BMC Infect Dis.* 2016;16:433. 7. Ostrowsky B, et al. *MMWR Morb Mortal Wkly Rep.* 2020;69:6-9.

This educational initiative was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC-RFA-CK20-2003) to the University of Alabama at Birmingham. The University of Alabama at Birmingham is collaborating with the Mycoses Study Group Education & Research Consortium and Terranova Medica, LLC, on this initiative. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.